Article Versions Notes

Giannitsis E, Garfias-Veitl T, Slagman A, Searle J, Müller C, Blankenberg S, von Haehling S, Katus HA, Hamm CW, Huber K, et al. Biomarkers-in-Cardiology 8 RE-VISITED—Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome—A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 Trial. Cells. 2022; 11(2):211. https://doi.org/10.3390/cells11020211

Giannitsis, Evangelos, Tania Garfias-Veitl, Anna Slagman, Julia Searle, Christian Müller, Stefan Blankenberg, Stephan von Haehling, Hugo A. Katus, Christian W. Hamm, Kurt Huber, and et al. 2022. "Biomarkers-in-Cardiology 8 RE-VISITED—Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome—A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 Trial" Cells 11, no. 2: 211. https://doi.org/10.3390/cells11020211

Giannitsis, E., Garfias-Veitl, T., Slagman, A., Searle, J., Müller, C., Blankenberg, S., von Haehling, S., Katus, H. A., Hamm, C. W., Huber, K., Vollert, J. O., & Möckel, M. (2022). Biomarkers-in-Cardiology 8 RE-VISITED—Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome—A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 Trial. Cells, 11(2), 211. https://doi.org/10.3390/cells11020211